KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Edwards Lifesciences (EW) Gross Margin (2016 - 2025)

Edwards Lifesciences has reported Gross Margin over the past 17 years, most recently at 78.15% for Q4 2025.

  • Quarterly results put Gross Margin at 78.15% for Q4 2025, down 77.0% from a year ago — trailing twelve months through Dec 2025 was 78.01% (down 144.0% YoY), and the annual figure for FY2025 was 78.01%, down 144.0%.
  • Gross Margin for Q4 2025 was 78.15% at Edwards Lifesciences, roughly flat from 77.77% in the prior quarter.
  • Over the last five years, Gross Margin for EW hit a ceiling of 122.98% in Q4 2022 and a floor of 75.7% in Q2 2021.
  • Median Gross Margin over the past 5 years was 78.78% (2025), compared with a mean of 80.91%.
  • Biggest five-year swings in Gross Margin: skyrocketed 4626bps in 2022 and later plummeted -4280bps in 2023.
  • Edwards Lifesciences' Gross Margin stood at 76.72% in 2021, then soared by 60bps to 122.98% in 2022, then tumbled by -35bps to 80.18% in 2023, then dropped by -2bps to 78.91% in 2024, then decreased by -1bps to 78.15% in 2025.
  • The last three reported values for Gross Margin were 78.15% (Q4 2025), 77.77% (Q3 2025), and 77.52% (Q2 2025) per Business Quant data.